OUR LEADERSHIP

Dr. Yvonne Greenstreet joined Alnylam in 2016 as Chief Operating Officer, was promoted to President and COO in 2020, and was appointed as a Director and Chief Executive Officer in late 2021. Yvonne has more than 25 years of experience in the Biopharmaceutical industry, driving strategy and innovation, bringing transformative medicines to patients, and building successful businesses in the US, Europe and globally.

Between 2011 and 2013, Yvonne was Senior Vice President and Head of Medicines Development at Pfizer serving on the executive team leading a rapidly growing $16bn division. Prior to Pfizer, she was at GlaxoSmithKline plc for 18 years, where she was Senior Vice President and Chief of Strategy for Research and Development. Yvonne had previously been in various positions of increasing responsibility at GSK, including Senior Vice President for Medicines Development and Chief Medical Officer for Europe.

Yvonne trained as a physician and earned her medical degree (MBChB) from The University of Leeds in the UK. She also holds an MBA from INSEAD Business school in France. She serves on the board of directors of The American Funds. Yvonne is a member of Bill and Melinda Gates Foundation Scientific Advisory Committee, the Discovery Council of Harvard Medical School, and the Council on Foreign Relations. She is also a member of the Biotechnology Industry Organization Health Section Governing Board and the board of the Biomedical Science Careers Program. Yvonne was recognized as the Healthcare Businesswomen’s Association 2024 Woman of the Year.

Dr. Pushkal Garg joined Alnylam in 2014 with 15 years of experience in clinical drug development. He oversees all clinical development activities at Alnylam as Chief Medical Officer and Executive Vice President of Development and Medical Affairs.

Prior to joining Alnylam, Dr. Garg served as Vice President, Global Clinical Research, Immunoscience at Bristol-Myers Squibb (BMS). He was the strategic leader of the Immunoscience franchise and oversaw the development of multiple clinical assets across the areas of rheumatology, gastroenterology, nephrology, and transplantation. While at BMS, he was instrumental to the late-stage development and approval of Nulojix® (belatacept) for kidney transplant recipients, and for supplementary biologics license applications (BLAs) for Orencia® (abatacept). Preceding this, Dr. Garg held various roles at Millennium Pharmaceuticals, overseeing the clinical development of multiple small molecule and biologic therapeutics for the treatment of inflammatory disorders.

Dr. Garg received a Bachelor of Arts with high honors in Biochemistry from the University of California, Berkeley, and his M.D. from the University of California, San Francisco. He completed residency training in Internal Medicine at UCSF, was a fellow in the Robert Wood Johnson Clinical Scholars Program at Johns Hopkins University, and served on the faculty of Harvard Medical School and the Brigham & Women’s Hospital in Boston prior to joining the industry.

Jeff Poulton joined Alnylam as CFO in August 2019. Prior to joining Alnylam, Jeff served as Chief Financial Officer at Indigo Agriculture, a plant microbiome company, from January 2018 to April 2019, where he supported the initial commercial scale-up of the business, including expansion outside the US.

Between 2003 and December 2017, Jeff held various roles of increasing responsibility at Shire Plc, culminating in his service as Chief Financial Officer and a member of Shire’s Executive Committee and Board of Directors from January 2015 to December 2017. During his tenure at Shire, Jeff also led Shire’s rare disease US, LATAM, and Asia Pacific commercial operations, as well as Shire’s global rare disease business unit. Prior to Shire, Jeff led corporate finance and business development initiatives in both the gas and electric utilities industry and the materials manufacturing sector, serving in financial leadership positions at Cinergy Corp and PPG Industries. Jeff also served in the United States Navy as a Commissioned Officer.

Jeff holds a BA in Economics from Duke University and an MBA in Finance from the Kelley School of Business at Indiana University. He is a member of the Board of Directors of CervoMed Inc.

Bob Hesslein joined Alnylam as Chief Legal Officer and Corporate Secretary in September 2024. Bob’s career embraces over 45 years of distinguished experience as an attorney and executive, including over 25 years working in biotech.

Most recently, Bob served as Senior Vice President, General Counsel and Chief Compliance Officer at Voyager Therapeutics. Before Voyager, Bob served as Senior Vice President, General Counsel, and Chief Compliance Officer at Foundation Medicine (now a subsidiary of Roche), a cancer diagnostics pioneer, where he was instrumental in supporting the company’s rapid development and growth. Prior to Foundation Medicine, Bob was Senior Vice President and Deputy General Counsel at Genzyme Corporation, serving in increasingly senior positions and playing a central role in the global growth of Genzyme’s legal organization. Prior to Genzyme, Bob served as a Vice President and Senior Counsel at New England Mutual. Bob began his legal career at the Boston-based law firm of Csaplar & Bok, specializing as an associate and as a partner in the general corporate, securities and finance areas.

Bob earned his Bachelor of Arts degree from Yale University, and his Juris Doctorate from Cornell Law School.

Kelley Boucher joined Alnylam in 2019 bringing nearly 20 years of experience within the biotechnology and medical device industries. She oversees the global HR organization which includes talent planning & strategy, organizational effectiveness, talent acquisition, learning & development, total rewards, and HR systems.

Prior to Alnylam, Kelley served as Vice President and Global Head of Human Resources at Abiomed for three years as the company experienced exponential growth and commercial execution. Before her time at Abiomed, Kelley spent 10 years at Shire where she held a variety of roles across HR, eventually becoming Vice President and Head of Human Resources for Technical Operations and then Shire’s Corporate Divisions. She also managed the organizational design component of multiple acquisitions. Prior to Shire, Kelley was a Principal Consultant at Clockwork Consulting (a pharmaceutical recruitment firm) and worked at Syntonix Pharmaceuticals (acquired by Biogen) and Digitas. She was honored with the Healthcare Business Women’s Association Rising Star award in 2013. Kelley is a member of the Healthcare Business Women’s Association (HBA), the Human Resources Leadership Forum (HRLF) and the Corporate Executive Board (CEB).

Kelley attended Cornell University where she received her Bachelor of Arts in government relations and the Darden School of Business at the University of Virginia where she completed her studies in the Strategic Leadership Development executive program.

Tim Maines joined Alnylam in August 2017 as the Global Head of Quality Assurance and Quality Control and was promoted to Chief Technical Operations and Quality Officer in April of 2023, holding over 35 years of experience. Prior to joining Alnylam, Tim was a member of the senior leadership teams at Ariad Pharmaceuticals, Omthera Pharmaceuticals, Astra Zeneca/MedImmune, GTC Biotherapeutics (formerly Genzyme Transgenics) and Stryker Biotech where he provided strategic input and independent quality and technical oversight of each company’s global GxP operations. In total, these experiences resulted with the commercialization and market expansion of thirteen novel medicines, including four FDA-approved therapies at Alnylam.

Tim holds a Bachelor of Science in Biology/Microbiology from Gannon University.

Tolga Tanguler joined Alnylam in January 2021 as Executive Vice President and Chief Commercial Officer with more than 20 years of experience in the global biopharmaceutical industry. At Alnylam, Tolga plays a pivotal role in scaling the company on a global stage, having expanded its commercial presence to more than 60 markets and tripled the number of patients served and product sales within three years.

Tolga has led commercialization efforts across a broad range of therapeutic areas, from early development to product launch and growth management. His leadership portfolio includes well-known medicines such as Viagra, Eliquis, and Ultomiris. Prior to Alnylam, he served as Head of U.S. at Alexion, where he led its transformational growth through first-in-class neurology product launches. Tolga spent most of his formative years at Pfizer, where he notably established and led the North America rare disease unit as its president, spearheading the company’s gene therapy innovation efforts.

Tolga holds a Bachelor of Science in Finance and Economics from Istanbul University and an MBA in Marketing and Supply Chain Management from Michigan State University. He also completed postgraduate studies in Marketing at the University of California, Santa Barbara. Tolga is a member of the Board of Directors of Lexeo Therapeutics, a clinical stage genetic medicine company.

Piyush Sharma joined Alnylam as Chief Ethics & Compliance Officer in August 2022. Piyush is an accomplished compliance leader with over 20 years of experience building best-in-class compliance programs across multiple industries including pharmaceutical, energy, and technology. Prior to joining Alnylam, Piyush was at Alexion Pharmaceuticals for five years where he was the Head of Compliance, managing all aspects of the Company’s compliance program, including a team of 25 Country and Regional Compliance Officers covering operations in over 50 countries. Before his time at Alexion, Piyush led anti-corruption compliance at Cognizant Technology Solutions and at Hess Corporation. He also held various compliance positions at Pfizer, including acting as the Chief Compliance Counsel for the Oncology and Emerging Markets Business.

Piyush attended Brown University where he received his Bachelor of Arts degree and went on to obtain his Juris Doctorate from Fordham University School of Law.

Christine Lindenboom joined Alnylam in 2015 as Vice President, Investor Relations & Corporate Communications, was promoted to Senior Vice President, Investor Relations & Corporate Communications in 2019, and was promoted to Chief Corporate Communications Officer in 2024. Christine leads a multidisciplinary team responsible for external & internal communications, corporate responsibility, brand and creative and investor relations. During her time at Alnylam, she has helped scale the company globally, launched 5 products in 4 years, and contributed to building its award-winning culture.

Before joining Alnylam, Christine served as Senior Director, Corporate Communications at Pfizer where she supported internal and external communications for R&D, and also served in various roles in media relations. Before her time at Pfizer, she led corporate media relations for Amgen, supporting executive, tax, litigation, finance and M&A. In her prior role at Amgen, she led communications for the oncology therapeutics franchise and led launch communications for XGEVA and VECTIBIX. Prior to joining Amgen, she worked at FleishmanHillard, a public relations firm, supporting various pharmaceutical and biotech clients, and she started her career in the communications group of Millennium Pharmaceuticals, where she helped launch VELCADE.

Christine is a member of the Board of Directors of Invivyd, Inc., a clinical-stage biopharmaceutical company. She received a Bachelor of Arts from Northeastern University.

Evan Lippman joined Alnylam in September of 2022 as Chief Corporate Development and Strategy Officer bringing with him many years of experience in corporate finance, business development, operational, and commercial roles spanning both large pharmaceutical and emerging biotechnology companies.

Evan joined Alnylam from Intima Bioscience where he served as President and Chief Operating Officer. Prior to Intima, he was Senior Vice President Head of Corporate Development, M&A and Valuation for Takeda Pharmaceuticals for nearly five years. In this position he was responsible for developing, structuring, and negotiating global acquisitions, divestments, and commercially focused licensing/strategic collaborations. Evan also serves on the Board of Directors for MassBio.

Before his time at Takeda, Evan was Chief Business and Financial Officer of Aileron Therapeutics, General Manager at both EMD Serono and AstraZeneca and was at Pfizer as a senior business development executive.

Evan holds an MBA in Finance from Cornell University.

Dr. Kevin Fitzgerald joined Alnylam in 2005 as Associate Director of Research and has served in roles of increasing responsibility and leadership since that time. Kevin was promoted to Chief Scientific Officer of Alnylam in May of 2019; he is also Executive Vice President and Head of Research at Alnylam and has 24 years of drug discovery experience.

His achievements at Alnylam include leadership of the company’s RNAi delivery efforts, resulting in two clinically validated modes of siRNA delivery, and the development of Alnylam’s RNAi therapeutic novel class of medicines. He is an inventor on over 50 patents including the majority of Alnylam’s marketed and pipeline programs, as well as an author of over 50 papers including many in prestigious journals such as Nature, Cell, and New England Journal of Medicine. He has led multiple programs — including Alnylam’s inclisiran program — from discovery through pre-clinical development, regulatory submissions, and early clinical development. Prior to 2005, Kevin was at Bristol-Myers Squibb for 7 years.

Kevin received his Bachelor of Science in genetics from Cornell University and his doctorate in molecular biology from Princeton University/Columbia Medical School. He completed his post-doctoral fellowship in oncology at Harvard Medical School.  Kevin also serves on the Scientific Advisory Board of Generation Bio and is an independent board Director for Ovid Therapeutics.